The IDG Blog
In advance of the Executive Forum for the Pharma industry event in Sandton, IDG South Africa MD Joanne Walsh interviews Prince Juli
JW – Looking from outside-in; what sound regulatory frameworks will create economic growth in the Pharmaceutical Industry?
PJ – Every country needs a well thought out level of regulation for this sector particularly. It should govern the entire drug lifecycle from research to production, promotion, distribution and ultimately, consumption. Regulation needs to be far-sighted. It needs to be such that encourages scientists to zealously search for new and better drug remedies. It needs to be such that encourages drug companies and investors generally, to invest in drug research. It also, very importantly, needs to protect the consumer. The regulator, needs to bite and not just bark. Regulation should be fair and focus on encouraging research, ensuring the delivery of quality drugs, as well as protecting the industry in general by facilitating ease of doing business. So a good regulatory framework will embody all of these. And good implementation would require sound collaboration between the regulatory body, political body and industry with fairness as a core value.
JW – An issue facing the industry in South Africa is the influx of counterfeit products. What is your opinion on this issue?
PJ – The organisers of this forum have been very wise to select this topic. Counterfeiting is on the rise, especially in emerging economies and needs to be aggressively curtailed early on. Counterfeit and fake products cut across many aspects of life including fashion, cars, technology and others. The issue with counterfeit drugs is the danger. Developing nations are reaching a level of up to 60% of fake products in their inventory. Thankfully, technology has proven to be a good ally to governments and regulators in the battle against this scourge of fake and counterfeit products. This is a good time to discuss what we can do across the continent to get this under control. As we embark on a way forward, we should ask – Why we are where we are? There are some fundamental issues to keep in mind.
JW – What policies and actions do you recommend to protect industry and consumers from the menace of rogue operators?
PJ – In Nigeria we established The National Agency for Food & Drug Administration and Control (NAFDAC). This came into existence in 1993 during my term as Minister of Health. They were empowered to make an impact in many spheres impacting the industry including import, export, advertising, manufacturing, distribution, sales and use of drugs. This is a difficult job, and every nation needs a strong regulatory body. To ensure their strength they need back-up to build capacity. However, it is not enough to have a regulator, such a regulatory body also needs to be properly funded such that it has the right equipment and adequate and well-trained manpower to deliver real value to society. Regulatory bodies also need to have the right leadership.
Technology is also key. I talked about mobile authentication service, earlier which has recorded good successes with detecting fake and counterfeit medicines. With well over 100 million active cell phone users in Nigeria, NAFDAC saw an opportunity in the deployment of MAS which essentially works via mobile phones. So, anyone wishing to buy an antibiotic or antimalarial, two of the most counterfeited products in our market, is able to confirm the authenticity of these medicines within seconds while in the pharmacy. True, there are occasional false negatives with sometimes bad consequences including reputation-loss especially for the pharmacies, but on the whole, MAS system is a welcome development. I understand that NAFDAC has also successfully used TRUSCAN which employs a similar technology to resounding success at country borders and elsewhere across Nigeria to detect counterfeit and fake medicines on the spot. So technology is clearly very critical in this battle and we must seek creative ways by which to more aggressively deploy it. Instructively, the beauty of deploying technology especially in the manner in which MAS has been deployed, is that it empowers consumers to become involved in the authentication of drugs and other products. So it supports advocacy and encourages consumer safety and involvement.
Thirdly, I would add that social advocacy is very important. There is plenty of room for education and enlightenment. People need to be taught some of the tell-tale signs of fake products and schooled on why it is important to avoid these products and how.
JW – Collaboration is a key value, very dear to IDG. Can you share your experience with the power of collaboration as key driver in the healthcare realm?
PJ – One quintessence of the power of collaboration in healthcare would be the global extermination of polio. This was a project that was spearheaded by Rotary International. In 1979 Rotary wanted to exterminate polio in Malaysia. Inspired by their success, in 1985 they committed to eradicating polio all over the world. They collaborated across nations, with civil society, volunteers and institutions. At the time they took this decision there were 350 000 reported cases of polio. By 2014 this number dropped to 400. Number of polio cases globally today, would be certainly negligible and a far cry from what it was a few decades ago. This is the power of collaboration.
JW – What does the state of healthcare look like on the African continent?
PJ – Africa is making efforts to make healthcare better. Rwanda is a country that does particularly well, with Ghana, Kenya and South Africa achieving progress. South Africa is good, but we all need to strive ceaselessly to make the current goodness better.
While on the one hand, I am tempted to commend some of the improvements that have been recorded, the indices are not very encouraging and sometimes make one question if indeed we are making progress in the right quantum. Recently the WHO raised an alarm about the resurgence of the Neglected Tropical Diseases in many parts of the continent. These are diseases like
Guinea Worm, Lymphatic Filariasis, Schistosomiasis, Onchocerciasis, and many others. A good number of these diseases can actually, be totally eradicated by mass drug administration and other interventions like the provision of clean water and proper waste disposal facilities. So clearly, there is still so much that needs to be done in Africa with regard to healthcare. Providing such important basics as clean water, ensuring good sanitation and proper waste disposal would go a long way at helping to redress these challenges.
JW – What is your final advice to improve healthcare delivery and eradicate illicit pharmaceutical product trade, on the continent?
PJ – My advice is to encourage government to reduce poverty. This encompasses fiscal, environmental and mental poverty. This will therefore also include investing a lot more in education. Mental poverty leads to ignorance which in-turn can be harmful to consumers. Better education always has a salutary impact on all other aspects of life including susceptibility to certain diseases and even deception by drug fakers and counterfeiters. Policy stability, advocacy and stakeholder collaboration across nations is paramount. The continent also needs to look more ambitiously at eradicating diseases that are prevalent in the continent especially the communicable ones. We need to do a better job of funding research as well as domesticating drug manufacture. We need to evolve from the donor-mentality where we consistently look up to developed nations to help solve our most basic health challenges, to a can-do mentality where we decide to rally our resources to solve our problems ourselves. All this has been said before, yet I need to reiterate the need to go from a Knowledge World to a Humane World. The highest ethical standards will result in products that are more humane, and stability will create prosperity.
Joanne Walsh is the Managing Director of Inspirational Development Group, South Africa (IDG-SA).
Joanne’s extensive global experience, her intimate understanding of shareholder value and investor confidence in the world of capital markets, along with her passion to raise the bar for individuals, teams and organisations ensures that IDG’s business performance engagements deliver ROI.
“IDG-SA is a business performance company with access to truly extraordinary client interventions across the globe. Our global faculty of subject matter experts ensures that our leadership, followership and partnership model fully serve the cross-functional business processes, leveraging functional competencies and fulfilling behavioural change required to raise the commercial excellence bar.” – Joanne Walsh
Get in Touch
Connect With Us
[gravityform id=”23″ title=”false” description=”false”]
How did you choose your leadership persona? Or did it perhaps chose you? Many managers […]Read More
Thinking outside the box While I appreciate the sentiment and applaud the idea of creative […]Read More
One of the big challenges to an effective Diversity and Inclusion programme is that the […]Read More
Following a tumultuous couple of years, many leaders & managers – and those with aspirations […]Read More
Royal Berkshire Hotel
+44 (0) 207 798 2848
Tower 2, Montreal Business Center
+91 955 271 5800
PO Box 1982, P.C. 111
Maktabi 1 Building,
The Sultanate of Oman
+971 56896 4262
+971 50550 8482
Cape Town, ZA
+27 (0) 21 492 7300